



Benign Prostatic Hyperplasia (YBPH-2): sc-69650

BACKGROUND

Benign Prostatic Hyperplasia (BPH), also known as benign enlargement of the prostate (BEP), is a condition that characterized by an increase in prostate size due to the formation of large nodules in the periurethral region of the prostate. Common in middle-aged and elderly men, Benign Prostatic Hyperplasia leads to an obstruction of the urethra, thus interfering with normal urine flow and causing an urgency to urinate, as well as a decrease in urine flow. In some instances, Benign Prostatic Hyperplasia can lead to recurrent urinary tract infections, bladder stones and kidney failure. These more serious afflictions are a direct result of an increase in the bacterial count within the bladder, a common phenomenon when urine flow is compromised. While mild cases of Benign Prostatic Hyperplasia can be treated by a simple decrease in fluid intake, moderate to severe cases generally require medical treatment in the form of oral drugs or prostate surgery.

REFERENCES

- Jacobsen, S.J. 2007. Risk factors for Benign Prostatic Hyperplasia. *Curr. Urol. Rep.* 8: 281-288.
- Edwards, J.L. 2008. Diagnosis and management of Benign Prostatic Hyperplasia. *Am. Fam. Physician* 77: 1403-1410.
- Hoke, G.P. and McWilliams, G.W. 2008. Epidemiology of Benign Prostatic Hyperplasia and comorbidities in racial and ethnic minority populations. *Am. J. Med.* 121: S3-S10.
- Emberton, M., Cornel, E.B., Bassi, P.F., Fourcade, R.O., Gómez, J.M. and Castro, R. 2008. Benign Prostatic Hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. *Int. J. Clin. Pract.* 62: 1076-1086.
- Dedhia, R.C. and McVary, K.T. 2008. Phytotherapy for lower urinary tract symptoms secondary to Benign Prostatic Hyperplasia. *J. Urol.* 179: 2119-2125.
- Miano, R., De Nunzio, C., Asimakopoulos, A.D., Germani, S. and Tubaro, A. 2008. Treatment options for Benign Prostatic Hyperplasia in older men. *Med. Sci. Monit.* 14: RA94-RA102.
- Isaacs, J.T. 2008. Prostate stem cells and Benign Prostatic Hyperplasia. *Prostate* 68: 1025-1034.
- Lepor, H., Lepor, N.E., Hill, L.A. and Trohman, R.G. 2008. The QT interval and selection of α -blockers for Benign Prostatic Hyperplasia. *Rev. Urol.* 10: 85-91.
- Rittmaster, R., Hahn, R.G., Ray, P., Shannon, J.B. and Wurzel, R. 2008. Effect of dutasteride on intraprostatic androgen levels in men with Benign Prostatic Hyperplasia or prostate cancer. *Urology* 72: 808-812.

SOURCE

Benign Prostatic Hyperplasia (YBPH-2) is a mouse monoclonal antibody raised against highly purified Benign Prostatic Hyperplasia of human origin.

PRODUCT

Each vial contains 100 μ g IgG kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Benign Prostatic Hyperplasia (YBPH-2) is recommended for detection of Benign Prostatic Hyperplasia of human origin by immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500); may cross-react with human prostate epithelial cells.

RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Immunofluorescence: use m-IgG κ BP-FITC: sc-516140 or m-IgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850. 2) Immunohistochemistry: use m-IgG κ BP-HRP: sc-516102 with DAB, 50X: sc-24982 and Immunohistomount: sc-45086, or Organo/Limonene Mount: sc-45087.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.